Benzothiazole derivatives and medicinal products containing them
    4.
    发明授权
    Benzothiazole derivatives and medicinal products containing them 失效
    苯并噻唑衍生物和含有它们的药用产品

    公开(公告)号:US5340824A

    公开(公告)日:1994-08-23

    申请号:US938153

    申请日:1992-12-02

    CPC分类号: C07D277/82

    摘要: ##STR1## Compounds of formula (I), in which R
    1 is a polyfluoralkoxy, R
    2 is a sulphur or nitrogen atom substituted by an alkyl radical or a sulfonyl or sulfinyl radical, R
    3 is a phenyl, benzoyl, --NR
    4 R
    5 or piperidinyl-4radical substituted in position 1 by a phenylalkyl radical, R
    4 is an alkyl radical, R
    5 is a phenylalkyl radical, n is equal to 1, 2 or 3, m is equal to 0, 1, 2 or 3. The present invention also relates to the salts of said compounds, processes for the preparation of the latter and drugs containing them.

    摘要翻译: PCT No.PCT / FR91 / 00437 Sec。 371日期1992年12月2日 102(e)日期1992年12月2日PCT提交1991年5月31日PCT公布。 WO91 / 18892 PCT出版物 (I)式(I)化合物,其中R 1是多氟烷氧基,R 2是被烷基或磺酰基或亚磺酰基取代的硫或氮原子,R 3是苯基 ,苯甲酰基,-NR4R5或哌啶基-4-取代的苯基烷基,R4为烷基,R5为苯基烷基,n等于1,2或3,m等于0,1,2或 本发明还涉及所述化合物的盐,其制备方法和含有它们的药物。

    2-iminobenzothiazoline derivatives, their preparation and pharmaceutical
compositions containing them
    5.
    发明授权
    2-iminobenzothiazoline derivatives, their preparation and pharmaceutical compositions containing them 失效
    2-亚氨基苯并噻唑啉衍生物,其制备方法和含有它们的药物组合物

    公开(公告)号:US5008280A

    公开(公告)日:1991-04-16

    申请号:US450231

    申请日:1989-12-13

    CPC分类号: C07D277/82

    摘要: Compounds of the formula: ##STR1## in which - R.sub.1 denotes a polyfluoroalkoxy or polyfluoroalkyl radical, and - R.sub.2 denoteseither a chain --CH.sub.2 --(CH(R.sub.4)).sub.n --R.sub.3, in which R.sub.3 denotes a dialkylamino, piperidino, 1-pyrrolidinyl, mercapto, acylthio, alkylthio, alkylsulphinyl or alkylsulphonyl radical, R.sub.4 denotes a hydrogen atom or an alkyl radical and n is equal to 0 or 1,or a residue of formula: ##STR2## the said alkyl and alkoxy radicals and portions containing 1 to 4 carbon atoms each in a straight or branched chain and said the acyl portions containing 2 to 4 carbon atoms each, and the salts of these compounds, are useful in the treatment of diseases in which glutamate is implicated.

    摘要翻译: 下式的化合物:其中-R 1表示多氟烷氧基或多氟烷基,-R 2表示链-CH 2 - (CH(R 4))n -R 3,其中R 3表示二烷基氨基,哌啶子基 ,1-吡咯烷基,巯基,酰硫基,烷硫基,烷基亚磺酰基或烷基磺酰基,R4表示氢原子或烷基,n等于0或1,或下式的残基:所述烷基和烷氧基, 各直链或支链含有1至4个碳原子的部分和所述酰基部分各自含有2至4个碳原子,并且这些化合物的盐可用于治疗涉及谷氨酸的疾病。

    5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives,
preparation thereof, intermediates thereof and drugs containing the same
    10.
    发明授权
    5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives, preparation thereof, intermediates thereof and drugs containing the same 失效
    5H,10H-咪唑并[1,2-a]茚并[1,2-e]吡嗪-4-酮衍生物,其制备方法,其中间体和含有它们的药物

    公开(公告)号:US5990108A

    公开(公告)日:1999-11-23

    申请号:US101428

    申请日:1998-07-09

    CPC分类号: C07D487/04 C07F9/6561

    摘要: Compounds of formula (I), wherein R is a hydrogen atom or a --COOH, -alk-COOH, --PO.sub.3 H.sub.2, --CH.sub.2 --PO.sub.3 H.sub.2, or --CH.dbd.CH--COOH radical, or a phenyl radical substituted by a carboxy radical, R.sub.1 is an alk-CN, -alk-COOH, -alk-Het, alk-PO.sub.3 H.sub.2 or -alk-CO--NH--SO.sub.2 R.sub.2 radical, R.sub.2 is an alkyl or phenyl radical, alk is an alkyl radical, Het is a saturated or unsaturated mono- or polycyclic heterocyclic ring containing 1-9 carbon atoms and one or more heteroatoms selected from O, S and N, said heterocyclic ring optionally being substituted by one or more alkyl, phenyl or phenylalkyl radicals, with the proviso that when R is a hydrogen atom or a --COOH or --PO.sub.3 H.sub.2 radical, R.sub.1 cannot be -alk-COOH, isomers, racemic mixtures, enantiomers and diastereoisomers thereof, salts thereof, the preparation thereof, intermediates thereof and drugs containing said compounds, are disclosed. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, and specifically ligands for NMDA receptor glycine modulator sites. ##STR1##

    摘要翻译: PCT No.PCT / FR97 / 00019 Sec。 371日期:1998年7月9日 102(e)日期1998年7月9日PCT 1997年1月6日PCT PCT。 出版物WO97 / 25328 日期:1997年7月17日式(I)化合物其中R为氢原子或-COOH,-alk-COOH,-PO3H2,-CH2-PO3H2或-CH = CH-COOH基,或苯基取代 通过羧基,R 1是烷基-C CN,-alk-COOH,-alk-Het,alk-PO 3 H 2或-alk -CO-NH-SO 2 R 2基团,R 2是烷基或苯基, Het是含有1-9个碳原子和一个或多个选自O,S和N的杂原子的饱和或不饱和单环或多环杂环,所述杂环任选被一个或多个烷基,苯基或苯基烷基取代,其中 条件是当R是氢原子或-COOH或-PO 3 H 2基团时,R 1不能是-alk COOH,其异构体,外消旋混合物,对映异构体和非对映异构体,其盐,其制备,其中间体和含有所述化合物的药物, 被披露。 式(I)化合物具有有价值的药理学性质,也是也称为quisqualate受体的α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂。 此外,式(I)化合物是N-甲基-D-天冬氨酸(NMDA)受体的非竞争性拮抗剂,特别是NMDA受体甘氨酸调节剂位点的配体。